

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

Ustekinumab for treating moderately to severely active Crohn's disease after prior therapy ID843

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Janssen (ustekinumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Colostomy Association • Crohn's and Colitis UK • For Crohns • IA: Ileostomy and Internal Pouch Support Group • Muslim Council of Britain • Ostomy Lifestyle Centre • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Coloproctology of Great Britain and Ireland • Association of Surgeons of Great Britain and Ireland • British Geriatrics Society • British Institute of Radiology • British Society of Gastroenterology • Primary Care Society for Gastroenterology • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal College of Surgeons of England • Royal Pharmaceutical Society 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • AbbVie (adalimumab) • Accord Healthcare UK (methotrexate) • Allergan (azathioprine, prednisolone) • Alliance Pharmaceuticals (prednisolone) • Almirall (balsalazide) • Amdipharm Mercury Company (hydrocortisone, methotrexate) • Aspen Pharma (azathioprine, mercaptopurine) • AstraZeneca UK (budesonide) • Kent Pharmaceuticals (methylprednisolone) • Dr Falk Pharma UK (budesonide) • Ferring Pharmaceuticals (mesalazine) • Focus (prednisolone)

APPENDIX C

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal Society of Medicine • Society and College of Radiographers • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • NHS Leeds West CCG • NHS West London CCG • Welsh Government 	<ul style="list-style-type: none"> • Hameln (methotrexate) • Hospira UK (infliximab, methotrexate) • Interpharm (prednisolone) • Merck Sharp & Dohme (infliximab) • Medac GmbH (methotrexate) • Napp (infliximab) • Nova Laboratories (mercaptopurine) • Orion Pharma UK (methotrexate) • Pfizer (hydrocortisone, methylprednisolone, methotrexate, sulfasalazine) • Rosemont (methotrexate, sulfasalazine) • Sandoz (azathioprine, methotrexate) • Takeda UK (vedolizumab) • Tillotts Pharma (mesalazine) • Warner Chilcott UK (mesalazine) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group • CORE - The Digestive Disorders Foundation • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland;; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.